A detailed history of Cibc Asset Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cibc Asset Management Inc holds 6,372 shares of BMRN stock, worth $447,887. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,372
Previous 6,047 5.37%
Holding current value
$447,887
Previous $528,000 0.76%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$74.43 - $92.22 $24,189 - $29,971
325 Added 5.37%
6,372 $524,000
Q1 2024

May 09, 2024

BUY
$83.81 - $99.0 $1,089 - $1,287
13 Added 0.22%
6,047 $528,000
Q4 2023

Feb 13, 2024

SELL
$76.22 - $98.51 $33,917 - $43,836
-445 Reduced 6.87%
6,034 $581,000
Q3 2023

Oct 30, 2023

BUY
$85.07 - $94.48 $13,185 - $14,644
155 Added 2.45%
6,479 $573,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $346 - $401
4 Added 0.06%
6,324 $548,000
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $27,287 - $36,470
311 Added 5.18%
6,320 $614,000
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $180,716 - $242,570
-2,233 Reduced 27.09%
6,009 $621,000
Q3 2022

Nov 03, 2022

BUY
$82.16 - $96.94 $1,807 - $2,132
22 Added 0.27%
8,242 $699,000
Q2 2022

Aug 09, 2022

SELL
$71.48 - $86.85 $255,112 - $309,967
-3,569 Reduced 30.27%
8,220 $681,000
Q1 2022

May 06, 2022

SELL
$74.28 - $92.69 $2.14 Million - $2.67 Million
-28,805 Reduced 70.96%
11,789 $909,000
Q4 2021

Feb 08, 2022

BUY
$71.72 - $91.47 $65,982 - $84,152
920 Added 2.32%
40,594 $3.59 Million
Q3 2021

Nov 09, 2021

BUY
$74.77 - $85.47 $475,985 - $544,102
6,366 Added 19.11%
39,674 $3.07 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $262,472 - $294,730
3,476 Added 11.65%
33,308 $2.78 Million
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $1.73 Million - $2.1 Million
23,128 Added 344.99%
29,832 $2.25 Million
Q4 2020

Feb 03, 2021

SELL
$72.61 - $90.2 $887,439 - $1.1 Million
-12,222 Reduced 64.58%
6,704 $588,000
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $73,019 - $133,126
1,016 Added 5.67%
18,926 $1.44 Million
Q2 2020

Jul 28, 2020

BUY
$79.55 - $124.22 $56,321 - $87,947
708 Added 4.12%
17,910 $2.21 Million
Q1 2020

Apr 30, 2020

SELL
$71.37 - $96.85 $3.65 Million - $4.95 Million
-51,100 Reduced 74.81%
17,202 $1.45 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $3.32 Million - $4.46 Million
51,687 Added 311.09%
68,302 $5.78 Million
Q3 2019

Oct 30, 2019

SELL
$67.4 - $85.11 $27,364 - $34,554
-406 Reduced 2.39%
16,615 $1.12 Million
Q2 2019

Aug 05, 2019

BUY
$80.35 - $93.9 $47,486 - $55,494
591 Added 3.6%
17,021 $1.46 Million
Q1 2019

May 06, 2019

SELL
$84.2 - $98.62 $27,954 - $32,741
-332 Reduced 1.98%
16,430 $1.46 Million
Q4 2018

Feb 12, 2019

BUY
$80.14 - $106.07 $45,519 - $60,247
568 Added 3.51%
16,762 $1.43 Million
Q3 2018

Nov 02, 2018

BUY
$93.92 - $105.72 $31,932 - $35,944
340 Added 2.14%
16,194 $1.57 Million
Q2 2018

Aug 09, 2018

BUY
$76.01 - $99.03 $74,945 - $97,643
986 Added 6.63%
15,854 $1.49 Million
Q1 2018

Apr 30, 2018

BUY
$77.67 - $92.63 $12,038 - $14,357
155 Added 1.05%
14,868 $1.21 Million
Q4 2017

Feb 02, 2018

BUY
$80.76 - $95.13 $109,591 - $129,091
1,357 Added 10.16%
14,713 $1.31 Million
Q3 2017

Nov 06, 2017

BUY
$80.6 - $94.95 $1.08 Million - $1.27 Million
13,356
13,356 $1.24 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.